olanzapine and Pneumonia--Viral

A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption

Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins

Topics: Aged; Antipsychotic Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Stress Disorders, Traumatic, Acute

Topics: Adult; Betacoronavirus; Chemotaxis, Leukocyte; Colchicine; Coronavirus Infections; COVID-19; Dapsone; Humans; Interleukin-8; Neutrophils; Olanzapine; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2

Topics: Antipsychotic Agents; Australia; Betacoronavirus; Conscious Sedation; Coronavirus Infections; COVID-19; Databases, Factual; Delayed-Action Preparations; Delirium; Drug Monitoring; Humans; Incidence; Olanzapine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Syndrome

A 41-year-old man with no significant medical history presented with acute behavioural disruption on the background of a 1-day history of severe headache and a 10-day history of dry cough and fever. He was sexually disinhibited with pressured speech and grandiose ideas. His behaviour worsened, necessitating heavy sedation and transfer to intensive care for mechanical ventilation despite no respiratory indication. Investigations confirmed that he was positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neuroimaging and a lumbar puncture were normal. Initial screening for SARS-CoV-2 in the cerebrospinal fluid was negative although no validated assay was available. The patient's mental state remained abnormal following stepdown from intensive care. Psychiatric assessment found features consistent with acute mania, and he was detained under the Mental Health Act. This case indicates the need to consider COVID-19 in a wider series of clinical presentations and to develop a validated assay for SARS-CoV-2 in the cerebrospinal fluid.

Topics: Adult; Affective Symptoms; Betacoronavirus; Cerebrospinal Fluid; Clonazepam; Coronavirus Infections; COVID-19; Diagnosis, Differential; Emergency Medical Services; Headache; Humans; Male; Neuroimaging; Olanzapine; Pandemics; Pneumonia, Viral; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Psychotropic Drugs; SARS-CoV-2; Treatment Outcome

Topics: Antipsychotic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Health Personnel; Humans; Male; Middle Aged; Olanzapine; Pandemics; Pneumonia, Viral; Psychotic Disorders; SARS-CoV-2

In December 2019, the novel coronavirus (SARS-CoV-2) infection was first reported in Wuhan city, central China, which has spread rapidly. The common clinical features of patients with SARS-CoV-2 infection included fever, fatigue, and damage to the respiratory or digestive system. However, it is still unclear whether SARS-CoV-2 infection could cause damage to the central nervous system (CNS) inducing psychiatric symptoms.. Herein, we present the first case of SARS-CoV-2 infection with manic-like symptoms and describe the diagnosis, clinical course, and treatment of the case, focusing on the identifications of SARS-CoV-2 in the specimen of cerebrospinal fluid (CSF). The patient developed manic-like symptoms when his vital signs recovered on illness day 17. After manic-like attack, the detection of SARS-CoV-2 specific IgG antibody in CSF was positive, while the reverse transcriptase-polymerase chain reaction (RT-PCR) on CSF for the SARS-CoV-2 was negative. The patient received Olanzapine for treatment and his mood problems concurrently improved as indicated by scores of Young Manic Rating Scale (YMRS).. This is a single case report only, and the RT-PCR test for SARS-CoV-2 in CSF was not performed simultaneously when SARS-CoV-2 was positive in samples of sputum and stool.. This first case of COVID-19 patient with manic-like symptoms highlights the importance of evaluation of mental health status and may contribute to our understanding of potential risk of CNS impairments by SARS-CoV-2 infection.

Topics: Antibodies, Viral; Antipsychotic Agents; Antiviral Agents; Betacoronavirus; Bipolar Disorder; Brain; Chest Pain; China; Clinical Laboratory Techniques; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Testing; Darunavir; Dyspnea; Fever; Glucocorticoids; Humans; Indoles; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Olanzapine; Pandemics; Pharyngitis; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2

Topics: Adult; Antipsychotic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Delusions; Haloperidol; Humans; Involuntary Treatment; Lorazepam; Male; Olanzapine; Pandemics; Paranoid Behavior; Pneumonia, Viral; Psychotic Disorders; SARS-CoV-2; Social Isolation; Treatment Outcome

Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Creatine Kinase; Haloperidol; Humans; Influenza A Virus, H1N1 Subtype; Male; Middle Aged; Neuroleptic Malignant Syndrome; Olanzapine; Pneumonia, Viral; Schizophrenia; Treatment Outcome; Valproic Acid; Withholding Treatment